Safety implications of low-dose amitriptyline in neuropathic pain by Mifsud Buhagiar, Luana et al.
 pf.hapres.com 
Article 
Safety Implications of Low-Dose Amitriptyline in 
Neuropathic Pain 
Luana Mifsud Buhagiar 1,2,*, Marilyn Casha 3, Anton Grech 4,  
Benjamin Micallef 2, John Joseph Borg 2, Anthony Serracino Inglott 1,2, 
Godfrey LaFerla 3 
1 Department of Pharmacy, Faculty of Medicine and Surgery, University of 
Malta, Msida, MSD 2080, Malta 
2 Medicines Authority, Malta Life Sciences Park, San Ġwann, SĠN 3000, Malta 
3 Department of Surgery, Faculty of Medicine and Surgery, University of Malta, 
Msida, MSD 2080, Malta 
4 Department of Psychiatry, Faculty of Medicine and Surgery, University of 
Malta, Msida, MSD 2080, Malta 
* Correspondence: Luana Mifsud Buhagiar,  
Email: luana.mifsud-buhagiar.06@um.edu.mt; Tel.: +00356-79709140. 
ABSTRACT 
Background: Treatment guidelines in neuropathic pain list amitriptyline 
as a first-line option. Modest evidence on efficacy and safety concerns 
possibly shape the rationale behind dosing recommendations. An 
observational study was carried out to understand the usefulness of 
safety monitoring for this established medicine.  
Methods: Twenty-six (26) subjects were categorized into 2 groups: 13 
patients under pain management receiving 10 mg amitriptyline daily for 
less than 12 months, and 13 patients under psychiatric care receiving a 
daily dose of 25–75 mg for over 12 months. Dose-related reference ranges 
were calculated and blood levels were assessed for the case examples 
presented. Adverse events and ECGs were collated. QT intervals were 
corrected using Bazett’s and Fridericia’s formulae. Side-effect frequencies 
were evaluated both within the research groups, and in the broader 
perspective of spontaneous ADR reporting through EudraVigilance.  
Results: The applicability of dose-related reference ranges, considering 
confounding factors such as drug interactions and metabolizer status, is 
discussed. Patients in both groups reported on average three side-effects, 
with drowsiness being reported more significantly in the 10 mg group 
and possibly attenuating with time; an observation not replicated for dry 
mouth. ADR reports with non-granulated information limit the 
usefulness of the data retrieved. Comparison of QT corrected with 
Bazett’s and Fridericia’s formulae suggests that Bazett’s may 
overestimate the number of patients on amitriptyline with QTc 
prolongation.  
Conclusions: This research supports the adoption of evolving research 
observations to understand the implications of dosing recommendations 
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and safety assessments in attempt of delivering individualized treatment 
with minimal risk.  
KEYWORDS: amitriptyline; neuropathic pain; dosage regimen; 
regulatory information; clinical outcomes  
ABBREVIATIONS  
ADR, adverse drug reaction; CHMP, Committee for Medicinal Products for 
Human Use; CMDh, Co-ordination group for mutual recognition and 
decentralised procedures—human; ECG, electrocardiogram; EV-DAS, 
EudraVigilance Data Analysis System; FDA, Food and Drug 
Administration; HIV, human immunodeficiency viruses; IASP, 
International Association for the Study of Pain; ICSR, Individual Case 
Study Report; SmPC, Summary of Product Characteristics; SNRI, serotonin 
and noradrenaline reuptake inhibitor; TCA, tricyclic antidepressant. 
INTRODUCTION  
Neuropathic pain is “caused by a lesion or disease of the 
somatosensory system”, in contrast to the nociceptive origin of chronic 
pain arising from damage to non-neural tissue [1]. Population prevalence 
of pain with neuropathic properties is estimated to be around  
7–10 percent [2], although indications point towards 20 percent of adults 
in Europe being potentially affected [3]. The origin of neuropathic pain is 
complex with known causes including diabetic neuropathy, postherpetic 
neuralgia, amputations, trauma, and HIV infection. Notwithstanding the 
diversity in aetiologies, neuropathic pain is considered as a distinct 
clinical entity.  
Tricyclic antidepressants (TCAs), particularly tertiary amines like 
amitriptyline, are the most effectively studied antidepressants for the 
treatment of neuropathic pain. Pain relief is achievable at lower doses 
than those entailed in the treatment of depression, and is believed to be 
independent of the antidepressant effects of these drugs [4,5]. Multiple 
mechanisms are possibly involved, at central and peripheral locations, 
with amitriptyline modulating nociceptive and sensory processes at the 
receptor and ion channel level [6]. Postulations range from the effect on 
serotonin and noradrenaline along descending spinal pain pathways, to 
the influence of TCAs on histamine receptors, the modulation of sodium 
channels [7], and the differential regulation of opioid receptors [8]. 
Updated guidance from the Neuropathic Pain Special Interest Group of 
the International Association for the Study of Pain (IASP) recommends 
TCAs, serotonin and noradrenaline reuptake inhibitors (SNRIs), 
pregabalin, and gabapentin as first-line therapy. The systematic review 
and meta-analysis by Finnerup et al. [9] concluded that 16 out of the  
18 placebo-controlled trials, evaluating amitriptyline in a daily dose of 
25–150 mg, were positive. At the low doses prescribed for the control of 
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pain, adverse effects, particularly sedation and dry mouth resulting from 
the anti-muscarinic activity of amitriptyline, were still reported [10].  
Amitriptyline is readily absorbed in the gastro-intestinal tract, widely 
distributed throughout the body, metabolized in the liver and excreted in 
the urine. Systemic exposure is expected to be linear and predictable [11], 
albeit population pharmacokinetics and interpatient variability in the 
blood concentrations of amitriptyline and its metabolites may be 
influenced by the activity of cytochrome P450 subfamily enzymes, 
particularly CYP2C19 and CYP2D6, which are known to be subject to 
genetic polymorphism. The metabolic implications are further 
complicated by drug-drug-gene interactions occurring when another 
drug in the patient’s regimen affects the individual’s enzyme activity 
pertinent to amitriptyline, triggering potential predisposition to 
treatment failure or adverse events. Amitriptyline is the most 
anticholinergic antidepressant [12] and is associated with weight gain, 
sexual dysfunction, orthostatic hypotension and cardiotoxicity.  
The long list of drugs that cause QT prolongation features 
amitriptyline which has been implicated with the specific form of 
ventricular tachycardia known as torsades de pointes [13]. Upward et al. 
[14] reported ECG changes which included shortened sinus cycle length 
with doses of 150–200 mg amitriptyline daily, together with an 8% and 
10% prolongation of the PR interval and QRS duration, respectively. TCAs 
prolong the QTc predominantly by blocking the Na+ channel [15] with the 
effect being more pronounced by the inhibition of outward K+ channels 
[16]. Although ECG changes are most evident in over-dosage, it is 
suggested that tricyclic antidepressants may unmask subclinical 
dysfunctional sodium channels and trigger drug-induced sudden death in 
patients receiving chronic treatment [13].  
Since heart rate has a biophysical effect on the QT interval, formulae, 
commonly Bazett’s square root formula or Fridericia’s cube root formula, 
may be used for QT correction. Bazett’s prevails as the most popular 
route for obtaining QTc, despite Fridericia’s correction possibly being 
more precise at the extremes of physiological heart rate [13], as may be 
the case in patients receiving TCA therapy [17,18]. A number of published 
studies evaluating QTc prolongation and amitriptyline use, either specify 
the use of Bazett’s formula in their methods, or lack details on which 
formula was used for QT interval correction [14,19–25]. Such array of 
data emerging in the literature and adverse events reported during the 
post-marketing period, as collated in the EU database of suspected 
adverse drug reactions (ADRs)—Eudravigiliance, serve to update the 
official sources of product information. The EU-CMDh (Co-ordination 
group for mutual recognition and decentralised procedures—human) 
published its scientific conclusions in 2015 [26] with amendments to be 
included in the relevant sections of the Summary of Product 
Characteristics (SmPC) involving a warning on “QT interval prolongation”, 
and “electrocardiogram QT prolonged” as a common adverse reaction. 
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The US-FDA drug label for amitriptyline [27] also makes reference to 
cardiovascular adverse reactions and potential ECG changes.  
The US-FDA label differs from the SmPC for amitriptyline in the EU 
particularly with respect to the indications, with the former solely listing 
“the relief of symptoms of depression”. Following a review completed by 
the EU-CHMP (Committee for Medicinal Products for Human Use) in 2017, 
the harmonised prescribing information for amitriptyline in the EU also 
includes “treatment of neuropathic pain in adults” as a therapeutic 
indication. The assessment report [28] concludes that the evidence for 
specific conditions cannot be considered sufficient but was not deemed to 
preclude a general indication in neuropathic pain. This was reflected in 
the SmPC whereby, for neuropathic pain, the posology presents as 
follows: Recommended doses are 25–75 mg daily in the evening. Doses 
above 100 mg should be used with caution. The initial dose should be  
10–25 mg in the evening. Doses can be increased with 10–25 mg every  
3–7 days as tolerated. The dose can be taken once daily, or be divided into 
two doses. A single dose above 75 mg is not recommended. The analgesic 
effect is normally seen after 2–4 weeks of dosing. There appears to be 
emphasis on a gradual increase in the dose of amitriptyline to the lowest 
effective dose, in attempt of enhancing tolerability and attenuating 
side-effect severity.  
The 2017 CHMP assessment report [28] notes that twice daily dosing 
may be necessary for immediate release formulations, to limit sedation 
and ensure a 24-hour therapeutic coverage, possibly recognizing that the 
blood concentrations resulting from low-dose amitriptyline administered 
once daily potentially verge on sub-therapeutic. The latter may be 
particularly relevant for the 10 mg starting dose, which prescribers might 
feel most confident to adhere to over the proposed 2–4 weeks in which 
efficacy may be assessed, even though in the studies implicated to 
support the use of amitriptyline in the treatment of neuropathic pain, a 
10 mg daily dose is somewhat unobserved [29–37]. This study aimed to 
investigate the safety rationale of using low-dose amitriptyline for 
neuropathic pain, through comparison with the reasonably higher doses 
administered in the management of depression. The implications of dose 
recommendations on blood levels and reported adverse events are 
discussed.  
MATERIALS AND METHODS 
Outpatients of any gender, over 18 years of age, whose treatment plan 
includes the tricyclic antidepressant amitriptyline, were considered. The 
study population consisted of twenty-six (26) patients attending the 
psychiatric clinic or the pain clinic, suffering from depressive illness or 
neuropathic pain sufficiently severe to require therapy, with 
amitriptyline as monotherapy or as add-on, and follow up through the 
outpatients’ services of Mater Dei Hospital (MDH), Malta. Ethics approval 
for this study was granted by the University of Malta Research Ethics 
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Committee in July 2017 (Ref. 23/2017). Written informed consent was 
obtained from all subjects before the study. 
Subjects were categorized into two groups: thirteen (13) patients, 
being followed by a consultant psychiatrist, who had been receiving 
25–75 mg amitriptyline daily for over 12 months; and thirteen (13) 
patients, being followed by a consultant anaesthetist, who had been 
receiving 10 mg amitriptyline daily for less than 12 months. Patients 
confirmed adherence to the prescribed dosing regimen upon questioning. 
Concomitant medications were noted, as applicable. Routine renal and 
liver function tests were performed throughout, whereas results of 
therapeutic drug monitoring and genotyping for CYP2D6 and CYP2C19 
were made available as needed. Dose-related concentration (DRC) factors 
listed in the Consensus Guidelines for Therapeutic Drug Monitoring in 
Neuropsychopharmacology: Update 2017 [38] were used to estimate the 
lower and upper limit of the expected dose-related concentration range, 
by multiplying DRC factors (low, −SD; high, +SD) by the daily dose.  
The self-report Antidepressant Side Effect Checklist (ASEC), designed 
as part of the GENDEP project [39], which focuses on side-effects that 
have been previously associated with antidepressants, was utilized for 
compiling responses on adverse events [40]. Permission to use ASEC in 
this research was granted by The Royal College of Psychiatrists, London, 
UK. Patients were guided to score the 21 items indexed in ASEC, on a 
four-point scale (0 absent; 1 mild; 2 moderate; 3 severe), making note on 
whether the symptom was linked to amitriptyline. All patients 
underwent an electrocardiographic (ECG) examination, and each 12-lead 
ECG report was analyzed for heart rate, PR, QRSd, and QT corrected by 
the Bazett’s and Fridericia’s formulae.  
In attempt of reviewing the safety outcomes from a pharmacovigilance 
perspective, all Individual Case Study Reports (ICSRs) for amitriptyline and 
“dry mouth” or “sedation” as Preferred Terms (PTs, distinct descriptors for 
symptom/sign), were extracted, on 6 March 2019, from the EU database on 
ADRs—EudraVigilance, using the EudraVigilance Data Analysis System 
(EV-DAS). Adverse drug reaction (ADR) data retrieved was rationalized to 
determine the number of reports for dry mouth and for sedation, 
according to the daily dose administered. Reports which did not specify the 
dosage of amitriptyline were excluded from the dataset. 
Data analysis was conducted using Excel (Microsoft, WA) and SPSS 
Statistics 25 software (IBM Corporation, USA). Variables were reviewed 
using standard descriptive statistics and data distribution was evaluated 
for normality by the Shapiro-Wilk test. Pearson correlation test was used 
to explore relationship between continuous variables (e.g., heart rate and 
QTc). Fisher’s exact test was used when comparing categorical data (e.g., 
side-effect frequencies) in the two groups. The level of statistical 
significance was set at 0.05.  
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RESULTS 
Twenty-six (26) patients, 5 males and 21 females, were categorized in 
two groups of 13 patients each, with comparable age (range: 24–79 years). 
Table 1 gives an overview of the cohort. The inclusion of patients 
receiving 10 mg amitriptyline daily facilitated comparison of a dose 
which is typically started with in pain management practice, as opposed 
to the higher doses prescribed in psychiatry, particularly with respect to 
safety implications. It is not intended to infer conclusions on the efficacy 
of amitriptyline doses for the diverse range of pain conditions, 
particularly in view that the pain scores reported by the 13 pain subjects 
(as an average intensity over the 4 weeks prior to assessment, scored on a 
scale from 0 to a maximum of 10) varied between 3 and 10 (median of 6) 
between subjects.  
Table 1. Descriptive statistics. 
Cohort, N = 26 Amitriptyline dosing Age (yr) 
Mean ± SD 
Weight (Kg) 
Mean ± SD 
Number of concomitant 
drugs Median (range) 
Patients in pain management,  
n = 13 
10 mg daily for <12 months 54 ± 14 70 ± 12 1 (0–5) 
Patients in psychiatric care,  
n = 13 
25–75 mg daily for >12 months 
(mean, median = 50 mg daily) 
58 ± 16 81 ± 14 5 (0–10) 
Practical Dosing Inferences 
Published dose-related concentration (DRC) factors [38] were used to 
calculate the theoretically expected active moiety (amitriptyline + 
nortriptyline) concentration range for the relevant daily doses. The 
computed dose-related reference ranges and the therapeutic drug 
monitoring (TDM) concentrations observed in four of the subjects studied 
are reported in Table 2, as an example. Subjects 1–4 were identified on 
the basis of: (i) daily dose of 10 mg/25 mg/50 mg/75 mg; (ii) entire daily 
dose administered as one intake in the evening; (iii) steady-state achieved; 
(iv) blood withdrawn 12–15 hours after last dose for determination of 
concentrations in serum; (v) no significant hepatic or renal dysfunction; 
(vi) normal metabolizer phenotype determined from CYP2D6 and 
CYP2C19 genotyping. Normal metabolizer status for both the tested genes 
was reported for 14 patients (54%). The sample from 1 patient failed 
genetic testing and 11 patients (42%) had irregular metabolism reported 
for one or both genes. The case examples presented enable dose 
recommendations to be put into perspective with regards to the resulting 
blood levels in “normal” patients, without genetic polymorphisms or 
organ diseases impacting drug elimination. Other confounding variables, 
such as unreported non-adherence and drug interactions may still be 
present. Paroxetine was co-administered in 54% (7 out of 13) of the 
psychiatric patient population, whereas the 13 patients under pain 
management did not receive any concomitant CYP-inhibitors. This 
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pharmacokinetic approach may be particularly relevant for amitriptyline 
in the management of neuropathic pain, since the lack of a widely 
accepted therapeutic reference range in the pain indication might render 
a pharmacodynamic approach less appropriate.  
Table 2. TDM case examples for amitriptyline dosing range between 10 mg and 75 mg daily. 
Subject 
Daily 
dose 
Dose-related reference 
range, ng/mL (active moiety) 
TDM total concentration, ng/mL 
(amitriptyline + nortriptyline) 
Relevant concomitant drug 
1 10 mg 7.3–15.1 11.3 None 
2 25 mg 18.3–37.8 38.8 Citalopram—weak CYP2D6 inhibitor 
3 50 mg 36.5–75.5 54.2 None 
4 75 mg 54.8–113.3 137.4 Paroxetine—potent CYP2D6 inhibitor 
Clinical Safety Outcomes 
The ECG data was reviewed to identify potential: (1) PR interval 
prolongation, (2) widening of the QRS-complex, and (3) QT interval 
prolongation. In the assessment of the electrocardiographic reports, the 
PR interval was considered prolonged if >200 ms [41], the QRS-complex 
was considered widened if >120 ms [42], and the QTc interval was 
considered prolonged if >450 ms [43]. Figure 1(A) portrays QTc, as 
corrected by the Bazett’s formula (QTcB) and Fridericia’s formula (QTcF) 
for all patients, highlighting the differences between QTcB and QTcF as 
heart rate increases. Figure 1(B) depicts a significant correlation between 
the percentage difference QTcB–QTcF and heart rate (P < 0.01; Pearson 
correlation 1-tailed test). The data indicates that Bazett’s correction 
formula potentially underestimates QTc at heart rates below 60 bpm and 
overestimates QTc at elevated heart rates. Fridericia’s correction may be 
more appropriate in subjects with altered heart rates [43].  
Considering QTcB, 6 subjects would be considered to have their QT 
prolonged (2 in the 10 mg group and 4 in the higher-dose group) while 
considering QTcF only one patient (in the higher-dose group) is 
considered to have QT prolongation. QRS-widening was observed in one 
(1) patient per group, while two (2) patients had prolonged PR (both 
patients from the 25–75 mg amitriptyline group). The PR interval was 
observed to be diminished with increasing heart rate, supporting a 
documented inverse relationship between the two [44,45].  
Irrespective of the group—dose, duration of use, and 
indication—patients reported, on average, three (3) side-effects on ASEC 
which they associate to amitriptyline (median 3, range 0–8, in pain 
patients on 10 mg daily for less than 12 months; median 2, range 0–10, in 
psychiatry patients on 25–75 mg daily for over 12 months). Out of the  
21 symptoms in ASEC, insomnia and decreased appetite (listed as 
uncommon and rare undesirable effects in the EU-SmPC, respectively) 
were the only two not reported by any of the subjects. The most reported 
side-effect overall was drowsiness (14 out of 26, 54%), with subsequent 
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frequencies as follows: Drowsiness (54%) > Dry mouth (35%) > Blurred 
vision (19%) = Feeling like the room is spinning (19%) = Tremor (19%) > 
Constipation (15%) = Palpitations (15%) = Feeling light-headed on 
standing (15%) > Headache (12%) = Diarrhoea (12%) = Increased appetite 
(12%) = Problems with sexual function (12%) = Weight gain (12%) > 
Disorientation (8%) = Yawning (8%) > Nausea or vomiting (4%) = 
Problems with urination (4%) = Sweating (4%) = Increased body 
temperature (4%). 
(A) 
 
(B) 
 
Figure 1. (A) QT corrected with Bazett’s formula (QTcB) and Fridericia’s formula (QTcF) for each patient vs. 
Heart Rate. (B) Percentage difference between QTcB and QTcF vs. Heart Rate. 
Drowsiness was reported more frequently in pain patients on 10 mg 
daily for less than 12 months (11 out of 13, 85%) compared to psychiatry 
patients on 25–75 mg daily for over 12 months (3 out of 13, 23%). Fisher’s 
exact test two-tailed P value of 0.0048 suggests that the latter observation 
is statistically significant. The frequency of drowsiness contrasts with dry 
mouth, which tended to be reported more by psychiatry patients 
receiving higher amitriptyline doses for a longer time-frame compared to 
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pain patients on lower doses over a shorter course (6 out of 13, 46%; 3 out 
of 13, 23%; respectively). With respect to intensity, the highest reported 
score for dry mouth was 3 (severe), observed in 6 psychiatry patients and 
1 pain patient, whereas for drowsiness the highest score reported was 2 
(moderate), observed in 2 psychiatry patients and 9 pain patients.  
Spontaneous Safety Reports  
A total of 391 Individual Case Study Reports (ICSRs) were retrieved 
from EV-DAS; 310 ICSRs for amitriptyline and PT “dry mouth” and 81 
ICSRs for amitriptyline and PT “sedation”. A total of 164 cases of dry 
month were reported in patients on a daily amitriptyline dose of 10 mg 
(54, 32.9%) or 25–75 mg (110, 67.1%). A total of 28 cases of sedation were 
reported in patients on a daily amitriptyline dose of 10 mg (4, 14.3%) or 
25–75 mg (24, 85.7%). The outcomes, as summarized in Table 3, point 
towards higher reporting rates of both dry mouth and sedation for 
patients receiving 25–75 mg amitriptyline daily, as compared to a 10 mg 
daily dose. The patient population receiving 25–75 mg daily doses is 
possibly larger in size than that of patients prescribed 10 mg daily, which 
may in turn affect the estimates, just as could be the case for the 
numerous reports with unknown dose. 
Table 3. Analysis of Individual Case Study Reports for amitriptyline and “dry mouth” or “sedation”. 
Dry Mouth, N = 310 
Daily Dose 10 mg <10 or >10 but <25 mg 25–75 mg >75 mg Unknown 
n 54 15 110 22 109 
Sedation, N = 81 
Daily Dose 10 mg <10 or >10 but <25 mg 25–75 mg >75 mg Unknown 
n 4 3 24 15 35 
DISCUSSION 
Attempts to establish a therapeutic window for amitriptyline 
analgesia endured as distant as decades ago [46]. A number of 
randomized controlled trials identify 75 mg per day as the average 
effective amitriptyline dose in the treatment of neuropathic pain [47], 
with blood levels of the active moiety close to 100 ng/mL [5]. As for safety, 
an upper concentration limit of 350 ng/mL has long been reported, below 
which a patient’s risk for serious undesirable complications is low [48]. 
Retrospectively, TCAs in dosages below 100 mg per day showed no 
increase in the risk of sudden cardiac death [49].  
A 2015 Cochrane review [50] emphasized that good-quality evidence 
on the use of amitriptyline in neuropathic pain management is not clear 
and alluded to potential overestimation of efficacy. Looking into the 
studies considered by the research groups of both Moore [50] and 
Finnerup [9], amitriptyline is often initiated with a 12.5–25 mg dose, with 
subsequent increments. This might not be replicated in routine clinical 
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practice whereby caregivers tend to continue prescribing amitriptyline at 
a daily maintenance dose as low as 5–10 mg per day, cognizant, or 
possibly over-cognizant, of the safety concerns [51]. Gradual dose 
titration is facilitated by the availability of scored dosage forms, and thus 
practical considerations with respect to the accessible strengths may not 
be a major concern. The recent review of IASP’s Neuropathic Pain Special 
Interest Group (NeuPSIG) on drug treatment for neuropathic pain 
underlines amitriptyline for first-line use and describes it as the most 
studied tricyclic antidepressant (TCA), in daily doses between 25 and  
150 mg, with no evident dose-response effect. Multidimensional review of 
efficacy and adverse events is suggested in adopting a pragmatic 
approach whereby the TCA is initiated for 12 weeks, which is the ceiling 
duration studied in most trials, and thereafter withdrawn if there is no 
benefit. The recommendations are made in recognition that studies were 
marked by potential publication bias, large placebo effect and modest 
drug effects [52].  
The CHMP 2017 assessment report [28] notes that slow titration of 
amitriptyline doses shall attenuate severity of sedation and dry mouth, 
among other side-effects, and increase tolerability. This may explain the 
rationale of recommending a markedly low starting dose. Our results 
indicate that sedation may indeed become less problematic in the 
long-term, even if there is dose escalation. In the case of dry mouth, 
however, it appears to persist over months of amitriptyline use and is 
perceived to interfere sufficiently in the patients’ quality of life to merit 
reporting. This questions the notion that anticholinergic adverse effects 
of amitriptyline generally abate with continued treatment, and favors the 
consideration that anticholinergic symptoms may fluctuate in their 
occurrence [53] or tolerance does not necessarily develop during 
long-term medication [54]. 
Does the lack of a recognized therapeutic range for amitriptyline in 
neuropathic pain warrant starting therapy with one-fifth of the initial 
dose recommended in depressed adults, to be on the safe side? Should 
this be the approach adopted, clinicians must be guided with respect to 
the necessary examinations and apt assessment measures, expected 
chronology, inter- and intra- patient confounding factors, and possibly 
also the reporting tools available to enable informed developments in 
safety appraisals. The supposition that clinical outcomes correlate better 
with blood levels than doses delineates the scope of therapeutic 
monitoring [55,56]. As illustrated by the case examples presented in this 
paper, dose-related reference ranges may be used, independently of a 
therapeutic reference range, to identify potential pharmacokinetic 
abnormalities which may impact on a patient’s systemic exposure to 
amitriptyline [38]. Blood levels outside the expected range may serve as 
an alert to actively look for disease-related changes, altered drug 
excretory functioning, and gene polymorphisms or drug-interactions that 
trigger ultra-rapid or poor metabolism, as may be the case with 
Pharm Front. 2019;1:e190003. https://doi.org/10.20900/pf20190003 
 
Pharmaceutical Frontiers 11 of 17 
citalopram and paroxetine, at different levels [57]. Practical 
considerations, such as time, provider burden and pharmacoeconomics, 
although outside the scope of this text, may certainly influence the 
implementation prospects of the approach discussed whereby the cost of 
sampling, genotyping and monitoring blood levels approximated to 
around 170 Euro per patient. Irregular metabolism may not only 
influence the concentrations of amitriptyline and nortriptyline in blood, 
but also those of hydroxy metabolites that are potentially cardiotoxic [58] 
—an added concern which should further encourage ECG monitoring.  
The International Conference on Harmonisation (ICH) Guideline E14 
acknowledges the controversy over the most accurate QT correction 
available and recommends that corrections are performed using both the 
Bazett’s and Fridericia’s formulas, enabling detection of relevant effects 
on the QT/QTc interval [43]. The comparison of QT corrected with Bazett’s 
formula (QTcB) and Fridericia’s formula (QTcF) performed in this study 
supports research showing that the most widely adopted 
formula—Bazett’s—underestimates at heart rates below 60 bpm and 
overcorrects QTc values at elevated heart rates [15,59,60], which may be 
particularly relevant for amitriptyline cases whereby Bazett’s may 
overestimate the number of patients with QTc prolongation leading to the 
medication being potentially withheld as a safety measure [61].  
The use of Fridericia’s formula is recommended, particularly at high 
heart rate, and investigating QTc changes from baseline should provide 
better individualized patient monitoring. Our subjects were assessed at 
one point in time and categorized as having prolonged QTc or otherwise. 
This cannot be extrapolated to determine whether amitriptyline causes 
QT prologation, which, although it represents a recent safety warning 
added to the SmPC, is somewhat also controversial. Investigating QTc 
prolonging effects of TCAs in a sub-group from the Rotterdam study, 
Noordam and colleagues [62], demonstrated statistically significant QTc 
prolongation with amitriptyline, using Bazett corrected QTc interval, 
which was lost upon adjusting for the increase in heart rate. The authors 
inferred that Fridericia’s formula might be preferred and suggested 
prospective revision to the warnings put forward by regulatory bodies in 
that TCAs might not indeed be associated with QTc prolongation. The 
2018 review by Rochester et al. [18] included mixed studies conducted in 
neuropathic pain in which no significant impact on QTc was seen [21] or 
amitriptyline was reported to have significantly prolonged the QTc 
interval [22], although to a lesser extent than observed with doses used in 
depression. Caution is recommended in generalizing data, with practical 
distinction between studies on QT prolongation in overdose or toxicity, as 
opposed to standard clinical use. Our results substantiate that the method 
of QT correction may be critical in the interpretation of the data.  
Gender, age and confounding medical conditions or medications are 
known to impact on QT prolongation [18]. It is important to note that 
systematic causality assessment was not performed in the present study, 
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either for prolonged-QT, or any of the adverse reactions considered. Thus, 
pre-existing causality or coexistent disease/drug causality cannot be ruled 
out. Spontaneous reporting databases, which could represent a very 
useful resource for post-marketing safety assessment, may be limited by 
the poor data quality within the reports. While the undemanding 
disposition of the ADR reporting system may help mitigate the 
manifestation of under-reporting, follow-up of cases through contact 
between regulatory authorities and reporters, may lead to collation of 
more complete data with corresponding significance for developing 
further our understanding of safety implications. 
CONCLUSIONS 
Robust evidence, which typically emerges from randomized 
controlled trials, is deficient with respect to the use of amitriptyline in the 
treatment of neuropathic pain, particularly in patients who may present 
with complex histories, multiple comorbid disease states and 
co-medications [63]. Exclusion of such patients and merely focusing on 
“normal” subjects makes direct application of emerging evidence 
problematic. Clinical outcomes are determined by how amitriptyline is 
used in everyday practice. Inadequacies in dosing regimens, lengths of 
therapy, concordance, consistent monitoring, and quality ADR reporting 
may impact the real-world evaluation of the balance between therapeutic 
benefits and safety risks. 
This work provides supportive evidence on how evolving research 
observations may be practically applied to better understand the 
implications of dosing recommendations and safety assessments, even 
for established drugs. Further work is necessitated in developing the 
themes elucidated by this work. Modern-day science, generating 
exploitable individualized data, may mitigate the hesitation associated 
with the trial-and-error prescribing of amitriptyline and drive informed 
clinical judgement, coupled with sensible follow-up, aimed at alleviating 
pain with minimal risk.  
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